These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 23450334)
1. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334 [TBL] [Abstract][Full Text] [Related]
2. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital. Stone-Brown K; Naji M; Francioni A; Myers K; Samarendra H; Mushtaq-Chaudhry H; Heslop S; Sengupta S; Ross CC; Larkin F; Das M CNS Spectr; 2016 Feb; 21(1):60-9. PubMed ID: 26726766 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Velligan DI; Carroll C; Lage MJ; Fairman K Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616 [TBL] [Abstract][Full Text] [Related]
4. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program. Tang Y; Horvitz-Lennon M; Gellad WF; Lave JR; Chang CH; Normand SL; Donohue JM Psychiatr Serv; 2017 Jun; 68(6):579-586. PubMed ID: 28196460 [TBL] [Abstract][Full Text] [Related]
5. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Wheeler AJ Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732 [TBL] [Abstract][Full Text] [Related]
6. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector. Leslie DL; Rosenheck RA J Ment Health Policy Econ; 2003 Sep; 6(3):113-21. PubMed ID: 14646004 [TBL] [Abstract][Full Text] [Related]
7. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060 [TBL] [Abstract][Full Text] [Related]
8. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Kreyenbuhl JA; Valenstein M; McCarthy JF; Ganoczy D; Blow FC Psychiatr Serv; 2007 Apr; 58(4):489-95. PubMed ID: 17412850 [TBL] [Abstract][Full Text] [Related]
9. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. Constantine RJ; Andel R; McPherson M; Tandon R Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142 [TBL] [Abstract][Full Text] [Related]
10. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Taylor DM; Young C; Paton C J Clin Psychiatry; 2003 Jan; 64(1):30-4. PubMed ID: 12590620 [TBL] [Abstract][Full Text] [Related]
11. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Sernyak MJ; Rosenheck RA Psychiatr Serv; 2008 May; 59(5):567-9. PubMed ID: 18451019 [TBL] [Abstract][Full Text] [Related]
12. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014. Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308 [TBL] [Abstract][Full Text] [Related]
13. Ethnic comparisons of antipsychotic use in schizophrenia. Wheeler A; Humberstone V; Robinson E Aust N Z J Psychiatry; 2008 Oct; 42(10):863-73. PubMed ID: 18777230 [TBL] [Abstract][Full Text] [Related]
14. Impact of audit and feedback on antipsychotic prescribing in schizophrenia. Wheeler A; Humberstone V; Robinson E; Sheridan J; Joyce P J Eval Clin Pract; 2009 Jun; 15(3):441-50. PubMed ID: 19366393 [TBL] [Abstract][Full Text] [Related]
15. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242 [TBL] [Abstract][Full Text] [Related]
16. Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis. Lee LHN; Procyshyn RM; White RF; Woodward TS; Honer WG; Barr AM PLoS One; 2018; 13(8):e0199758. PubMed ID: 30096136 [TBL] [Abstract][Full Text] [Related]
17. Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used? Constantine RJ; Andel R; McPherson M; Tandon R Psychiatry Res; 2018 May; 263():238-244. PubMed ID: 29195836 [TBL] [Abstract][Full Text] [Related]
18. Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals. Latimer EA; Naidu A; Moodie EE; Clark RE; Malla AK; Tamblyn R; Wynant W Psychiatr Serv; 2014 Oct; 65(10):1210-7. PubMed ID: 24981557 [TBL] [Abstract][Full Text] [Related]
19. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit. Lerma-Carrillo I; de Pablo Brühlmann S; del Pozo ML; Pascual-Pinazo F; Molina JD; Baca-García E Clin Neuropharmacol; 2008; 31(6):319-32. PubMed ID: 19050409 [TBL] [Abstract][Full Text] [Related]
20. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]